Adding Talazoparib to Enzalutamide Boosts PFS in Metastatic Prostate Cancer
SAN FRANCISCO — Treatment with the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) significantly improved radiographic progression-free survival (rPFS) compared with enzalutamide plus placebo in patients with metastatic castration-resistant prostate cancer (mCRPC), the phase III TALAPRO-2 trial showed. Among 805 randomized patients, rPFS assessed by blinded independent central review was not reached in those who […]
Comorbidity Burden in People With HIV Tied to Increased Mortality Risk
The prevalence of comorbidities in people with HIV on effective antiretroviral treatment was consistently higher compared with HIV-negative individuals, and was linked to an increased risk for death, according to a prospective longitudinal cohort study. In people age 45 and older followed for a median 5.9 years, 5.2% of the 596 HIV-positive participants died compared […]
CATIS-2: Delayed Antihypertension Tx for Acute Ischemic Stroke Still an Option
DALLAS — Antihypertensive treatment could wait for 7 days following an acute ischemic stroke (AIS), so long as the patient has no comorbidities that warrant the emergency reduction of their blood pressure (BP). In the CATIS-2 trial, there was no significant difference in the composite of major disability and death between patients with AIS who […]
JAK Inhibitor Improves Symptoms, Anemia in Myelofibrosis
Myelofibrosis treatment with the Janus kinase (JAK) inhibitor momelotinib resulted in clinically significant improvements in symptoms and spleen response compared with danazol for symptomatic, JAK inhibitor-exposed patients with anemia and intermediate- or high-risk disease, the phase III MOMENTUM trial showed. A significantly greater proportion of patients in the momelotinib group reported a ≥50% reduction in […]
White House Drug Control Office Focused on Improving Treatment Access
Improving access to addiction treatment and disrupting the supply of illicit drugs will be the big goals this year for the Office of National Drug Control Policy (ONDCP), according to its director, Rahul Gupta, MD, MPH. One big order of business will be to fully implement the Mainstreaming Addiction Treatment (MAT) Act, which was included […]
FDA Approves First Gene Therapy for Non-Muscle-Invasive Bladder Cancer
The FDA has approved nadofaragene firadenovec (Adstiladrin) as the first gene therapy for the treatment of high-risk bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), the agency announced on Friday. An adenoviral vector-based product, nadofaragene firadenovec, is specifically indicated for adult patients with carcinoma in situ (CIS) with or without papillary tumors. Approval was based on […]
Opinion | Perfectionism Will Kill You
Every doctor wants to be perfect. We want to make sure our diagnosis is perfect. Our treatment plan is perfect, and our outcome will be perfect. Patients want the perfect doctor. They want us to get it right on the first try, each and every time. The problem is perfectionism, as hard as we try […]
Dietary change starves cancer cells, overcoming treatment resistance: Laboratory research finds a low-protein diet can enhance standard treatment for colon cancer
A dietary change could be a key to enhancing colon cancer treatment, a new study from the University of Michigan Rogel Cancer Center finds. Cancer cells need nutrients to survive and grow. One of the most important nutrient sensing molecules in a cell is called mTORC1. Often called a master regulator of cell growth, it […]
Monoclonals for COVID in Pregnancy Pass Safety Test, Efficacy on the Other Hand …
Monoclonal antibody treatment for COVID-19 was safe to use in pregnancy, but wasn’t all that effective, according to a single-center study. Among pregnant patients with mild-to-moderate COVID-19 who received monoclonal antibody treatment, infusion reactions were rare, with 1.4% of patients experiencing mild, drug-related adverse events (AEs), reported Erin McCreary, PharmD, of University of Pittsburgh Medical […]
State Insurance Mandates Don’t Improve Racial Disparities in ART Live Births
ANAHEIM, Calif. — Insurance mandates for fertility treatment with donor oocytes may improve overall live birth rates, but the current policies fail to reduce racial disparities in assisted reproductive treatment (ART), according to a retrospective study. Overall, state insurance requirements for coverage of donor oocytes were linked to a 10% increase in the odds of […]